People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $335.0M | $1.0B | 2023 |
Richard M. Heyman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard M. Heyman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mardi C. Dier | 1 | 2 |
| Lori L. Kunkel | 1 | 1 |
| Jacob M. Chacko | 1 | 1 |
| Dominic M. Piscitelli | 1 | 1 |
| Angie L. You | 1 | 1 |
| Pratik M. Multani | 1 | 1 |
| Steve L. Hoerter | 1 | 1 |
| Mardi M. Dier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.